| Customization: | Available |
|---|---|
| CAS No.: | 9087-70-1 |
| Formula: | C284h432n84o78r2s7 |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Hunan Yunbang Pharmaceutical Co., Ltd. (Yunbangpharm) located in Changsha High-tech Industrial Park, Hunan. It is a high-tech enterprise specializing in the research and development, production and sales of Pharmaceutical raw materials, Pharmaceutical intermediates(API) and Fine chemicals. Based in China, Yunbangpharm has been providing suitable solutions for many domestic,foreign pharmaceutical companies and traders. Excellent quality, good reputation and authentic price have won the praise of the majority of customers.
The company adheres to the corporate tenet of "We do not produce medicines, but help pharmaceutical companies make good medicines".Aprotinin is a polypeptide protein that acts as a potent and specific inhibitor of serine proteases. It is derived from bovine lung tissue and is recognized for its ability to effectively inhibit enzymes such as trypsin, chymotrypsin, and plasmin. Aprotinin's inhibitory activity against these proteases makes it a valuable tool in various biochemical, biotechnological, and medical applications.
In biomedical research and clinical settings, aprotinin has been utilized to reduce bleeding and blood loss during surgical procedures, particularly in cardiac and orthopedic surgeries. Its ability to inhibit fibrinolysis, the breakdown of blood clots, has made it beneficial in the management of excessive bleeding, contributing to improved patient outcomes during certain surgical interventions.
Aprotinin has also been investigated for its potential anti-inflammatory properties and its role in modulating immune responses. Additionally, it has been studied in the context of organ preservation and transplantation, where its inhibitory effects on proteases play a role in the protection of donor organs and tissues from damage during transplantation procedures.
Furthermore, aprotinin's utility extends to laboratory research, where it is employed as an inhibitor of serine proteases in various experimental protocols, including the purification and study of proteases, as well as in the development of therapeutic agents targeting serine proteases.
General description
1:Can I get some samples before bulk order?
A: Most products provide free samples, but the shipping cost be paid by customers.
2: What's your MOQ?
A: We can have a discussion.
3: Which kind of payment terms do you accept?
A: PI will be sent first after confirmation of order,enclosed our bank information.Payment by T/T, Western Union,D/P, ETC.
4.How to place an order?
A: You can contact me through Trademanager, WhatsApp, Email and other contact methods, tell me the product and quantity you need, and then we will give you a quote.
5:How about your delivery time?
A: Generally, it will take 3 to 5 days after receiving your advance payment.
6:How do you treat quality complaint?
A: First of all, our quality control will reduce the quality problem to near zero. If there is a real quality problem caused by us, we will send you free goods for replacement or refund your loss.
1. 90days quality guarantee for exchange.
2. For each batch order extracts, we will attach a factory Inspection Report with the goods delivery , including the BatchNo/ Date/ Test index ects; also will keep the archived extracts to ensure received by customers are the same each time.
3. Our team of experienced professionals are available online 24 hours a day to answer any questions and provide guidance on product usage and maintenance.
| Product Name: | Aprotinin |
| Synonyms: | TRYPSIN INHIBITOR, PANCREAS TYPE;TRYPSIN INHIBITOR (BASIC);TRYPSIN INHIBITOR, BOVINE LUNG;TRASYLOL;antikrein;antilysin;antilysine;aprotininfrombovinelung |
| CAS: | 9087-70-1 |
| MF: | C284H432N84O78R2S7 |
| MW: | 6495.43988 |
| EINECS: | 232-994-9 |
| Product Categories: | inhibitor;Affinity Chromatography;Protein Chromatography;Specialty Resins;ProteaseInhibitors |
| Mol File: | 9087-70-1.mol |
| Melting point | >234oC (dec.) |
| storage temp. | 2-8°C |
| solubility | glycerol: soluble3mg/mL, clear, colorless (equilibration buffer containing 5% glycerol) |
| form | lyophilized powder |
| color | white |
| Water Solubility | Freely soluble in water and in aqueous buffers of low ionic strength. |
| Merck | 13,761 |
| Stability: | Stable. Incompatible with strong oxidizing agents. |
| Hazard Codes | Xn,Xi |
| Risk Statements | 42/43-36/37/38-20/21/22 |
| Safety Statements | 22-45-36/37-36-26 |
| WGK Germany | 1 |
| RTECS | YN5080000 |
| F | 10-21 |
| HS Code | 35040000 |
| Hazardous Substances Data | 9087-70-1(Hazardous Substances Data) |
| Toxicity | LD50 i.v. in mice: 2500000 kallikrein inhibitor units/kg (Trautschold) |
| Chemical Properties | white powder |
| Originator | Trasylol,Bayer |
| Uses | Aprotinin is largely used as an inhibitor of trypsin. |
| Brand name | Trasylol (Bayer). |
| Therapeutic Function | Proteinase inhibitor |
| General Description | Trypsin inhibitor, pancreas type from bovine lung. It is known as Pancreatic trypsin inhibitor (BPTI). Aprotinin, also known as pancreatic trypsin inhibitor and trypsin-kallikrein inhibitor, is found to be expressed in lungs, spleen, liver, and pancreas. It is also found to be present in the free form in calf serum. |
| Biochem/physiol Actions | Aprotinin is a competitive serine protease inhibitor that forms stable complexes with and blocks the active sites of enzyme. This binding is reversible, and most aprotinin-protease complexes will dissociate at extreme pH levels >10 or <3. Structurally, Aprotinin is a monomeric globular protein derived from bovine lung that consists of 58 amino acids, arranged in a single polypeptide chain with three crosslinking disulfide bridges. |
| Safety Profile | Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx and SOx. |
| storage | Store at +4°C |
| references | 1. henry da, carless pa, moxey aj, et al. anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. cochrane database syst rev 2007; 4: cd001886.2. levi m, cromheecke me, de jonge e, et al. pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. lancet 1999; 354: 1940-7.3. sedrakyan a, treasure t, elefteriades ja. effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized |
){kind=link}